Ark gains on hopes for cancer drug
Thursday 31 July 2008
Ark Therapeutics, the gene therapy group, gave the beleaguered UK biotech industry a shot in the arm yesterday when it said that the third phase trial of its brain cancer treatment, Cerepro, has shown good initial results and that it now expects to be able to market the drug by next year.
The company's shares rocketed on the news closing the day up 69 per cent at 80.25p. Ark had earlier said that the topline results of the tests showed that patients using the treatment were on average surviving 42 days longer than people not using Cerepro.
The results come from tests on 183 patients with the company expected to give details of another 53 cases early next year, after which it will apply to European regulators for a licence to sell the drug.
Ibraheem Mahmood, an analyst at Investec, said that while yesterday's news was encouraging, the real tonic for the group is that the positive tests validate Ark's gene based technology and that should lead to interest from some of the pharmaceutical giants. "While the news is certainly good, it is really only a by-product," he said. "Cerepro will be worth between about $500m and $1bn, but it is the first time that the technology has been shown to work and that makes it appealing to buyers."
The news will also be welcomed by the wider UK biotech market, which has a poor record of converting potential drugs in trial into commercial successes. In recent weeks two other groups, Alizyme and Oxford Biomedica, have disclosed pivotal phase three failures, which sent the share price of both companies crashing.
However, the news on Cerepro was not greeted with universal praise. KBC analyst Paul Cuddon pointed out that Cerepro will need to compete against existing medicines. "In order for the trial to be considered a success, and for the company to claim they have a blockbuster, it has to show that it is better than what is already out there, and these trials do not show that," he said. "Ark needed to show that Cerepro is more effective than Temador [another brain cancer treatment] and they have not done that. I still have major concerns."
Mr Mahmood countered that Temador, which had annual sales of $861m last year, has side effects akin to the symptoms suffered by AIDS sufferers, giving patients a poor quality of life.
- 2 California man brutally beat 82-year-old Sikh grandfather he mistook for 'one of those people'
- 3 School kitchen manager 'fired from Colorado school for giving hungry students free lunches'
- 4 Amy Schumer: 'I'm 160lbs and can catch a d**k any time I want'
- 5 Isis executes three gay men by dangling them from top of 100ft building and letting go
Amber Peat: Body found in search for missing 13-year-old who left house after argument with her parents
School kitchen manager 'fired from Colorado school for giving hungry students free lunches'
Amy Schumer: 'I'm 160lbs and can catch a d**k any time I want'
Isis executes three gay men by dangling them from top of 100ft building and letting go
Alton Towers crash: Four guests seriously injured as Smiler ride carriages collide
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination
Migrants in Kos: Photos show real tragedy after Brits abroad complain of 'awkward' holidays
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
Michael Gove determined to scrap the Human Rights Act – even if Scotland retains it
Threat to scrap Human Rights Act could see UK follow Nazi example, warns UN official
Church of England 'one generation away from extinction' after dramatic loss of followers
iJobs Money & Business
£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...
£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...
£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...
£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...